2023
Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions
Smolderen K, Romain G, Provance J, Scierka L, Mao J, Goodney P, Henke P, Sedrakyan A, Mena-Hurtado C. Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. JACC Cardiovascular Interventions 2023, 16: 332-343. PMID: 36792257, PMCID: PMC10359106, DOI: 10.1016/j.jcin.2022.09.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalAngiotensin-Converting Enzyme InhibitorsHeart FailureHumansMedicareMiddle AgedStroke VolumeTreatment OutcomeUnited StatesConceptsGuideline-directed medical therapyPeripheral vascular interventionsMedical therapyVascular interventionsEnzyme inhibitors/angiotensin receptor blockersVascular Quality Initiative registryAngiotensin receptor blockersLong-term mortalityRisk of amputationRisk of mortalityNational quality registryQuality improvement effortsAmputation outcomesAmputation riskMajor amputationAntiplatelet therapyCause mortalityReceptor blockersMean ageVascular careQuality registryObservational studyMortality riskHigh riskAmputation dataThe use of evidence-based medical therapy in patients with critical limb-threatening ischaemia.
Bager L, Petersen J, Havers-Borgersen E, Resch T, Smolderen K, Mena-Hurtado C, Eiberg J, Køber L, Fosbøl E. The use of evidence-based medical therapy in patients with critical limb-threatening ischaemia. European Journal Of Preventive Cardiology 2023, 30: 1092-1100. PMID: 36708037, DOI: 10.1093/eurjpc/zwad022.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsComorbidityFemaleHumansMaleMyocardial InfarctionPeripheral Arterial DiseaseRetrospective StudiesRisk FactorsTreatment OutcomeConceptsEvidence-based medical therapyARB/ACEILimb-threatening ischaemiaMyocardial infarctionMedical therapyHistory of MIHigh-risk patientsFirst-time hospitalizationUnadjusted odds ratioYears of ageMore comorbiditiesPatients 40Hazard ratioDanish registriesOverall mortalityAdjusted analysisAdverse prognosisOdds ratioPractice patternsPatientsMortality rateACEIIschaemiaTherapyMortality
2021
Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
Llanos-Chea F, Jelani QU, Trejo-Paredes C, Curtis JP, Parzynski CS, Huang J, Faridi KF, Turner J, Smolderen KG, Mena-Hurtado C. Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia. Journal Of The American College Of Cardiology 2021, 77: 1374-1375. PMID: 33706882, DOI: 10.1016/j.jacc.2020.12.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCohort StudiesEndovascular ProceduresFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIschemiaMaleMiddle AgedPeripheral Arterial DiseasePlatelet Aggregation Inhibitors
2013
Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry
Smolderen KG, Spertus JA, Tang F, Oetgen W, Borden WB, Ting HH, Chan PS. Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry. Journal Of The American College Of Cardiology 2013, 61: 1069-1075. PMID: 23375933, PMCID: PMC3641586, DOI: 10.1016/j.jacc.2012.11.058.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAmbulatory CareAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDrug UtilizationFemaleHumansHypolipidemic AgentsInsurance, HealthMaleMedicaidMedically UninsuredMedicareMiddle AgedPlatelet Aggregation InhibitorsRegistriesUnited StatesUnited States Department of Veterans AffairsUnited States Indian Health ServiceConceptsCoronary artery diseaseUninsured patientsEvidence-based treatmentsInsurance statusARB therapyAngiotensin-converting enzyme inhibitors/angiotensin II receptor blockersEnzyme inhibitors/angiotensin II receptor blockersAngiotensin II receptor blockersNational Cardiovascular Data RegistryPublic insuranceEvidence-based medicationsLipid-lowering therapyII receptor blockersLeft ventricular dysfunctionHealth insuranceTreatment differencesPoisson regression modelsPINNACLE RegistryPhysician adherenceVentricular dysfunctionReceptor blockersArtery diseaseCardiac RegistryCardiac outpatientsData registry